Lluís Fumadó - Concepedia

Author

Lluís Fumadó

Also Known As

Ciutat Lluis Fumadó, Cristina Quicios-Dorado, L Fumado, L Fumadó Ciutat, L. Fumado, L. Fumado Ciutat, L. Fumadó, L. Fumadó Ciutat, L. Fumadó-Ciutat, L.I. Fumadó

Publications

500

Citations

H-Index

Concepts

All Affiliations

Universitat Pompeu Fabra Parc de Salut Hospital Del Mar Hospital del Mar Research Institute Universitat Autònoma de Barcelona

About

Lluís Fumadó is an author at Universitat Pompeu Fabra specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	46
2	Public Health	1	1	20
3	Epidemiology	1	1	20
4	Health Policy	1	1	20
5	Pathology	1	1	26

Lluís Fumadó

Publications

334

Citations

H-Index

Page 1

	Year	Citations
Association of <i>ERG</i> and <i>TMPRSS2‐ERG</i> with grade, stage, and prognosis of prostate cancer is dependent on their expression levels Alba Font‐Tello, Núria Juanpere, Silvia de Muga, The Prostate	2015	65
Prospective, Randomized, Open-Label, Fixed-Dose, Crossover Study to Establish Preference of Patients with Erectile Dysfunction After Taking the Three PDE-5 Inhibitors J. Rodríguez Tolrá, José María Cuadrado Campaña, Lluís Fumadó, The Journal of Sexual Medicine	2006	60
Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study Anna Sureda, Lluís Fumadó, Montse Ferrer, Health and Quality of Life Outcomes	2019	27
Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status Raquel Albero‐González, Silvia Hernández‐Llodrà, Núria Juanpere, Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin UrologyMedicinePathologyMismatch Repair ProteinsProstatic Disease	2019	26
Positive margins after nephron‐sparing surgery for renal cell carcinoma: long‐term follow‐up of patients on active surveillance M.Á. López-Costea, Lluís Fumadó, D. Lorente, British Journal of Urology	2010	24
ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression Silvia Hernández‐Llodrà, Núria Juanpere, Silvia de Muga, Oncotarget	2017	23
Preliminary results of the Spanish Association of Urology National Registry in Active Surveillance for prostate cancer J. Rubio‐Briones, Luis Esteban, I. Iborra, Actas Urológicas Españolas (English Edition) UrologyUrologic Cancer EpidemiologyHealth PolicyGenitourinary CancerMedicine	2015	20
<i>SPOP</i> and <i>FOXA1</i> mutations are associated with PSA recurrence in <i>ERG</i> wt tumors, and <i>SPOP</i> downregulation with <i>ERG</i>‐rearranged prostate cancer Silvia Hernández‐Llodrà, Laura Segalés, Ainara Safont, The Prostate	2019	20
Concurrent<i>TMPRSS2-ERG</i>and<i>SLC45A3-ERG</i>rearrangements plus<i>PTEN</i>loss are not found in low grade prostate cancer and define an aggressive tumor subset Sílvia Hernández, Alba Font‐Tello, Núria Juanpere, The Prostate	2016	18
Factors associated with the compensation of renal function after nephrectomy of a kidney donor Carla Burballa, Marta Crespo, Dolores Redondo‐Pachón, Nefrología (English Edition)	2018	14

Page 1